The FTSE 100 fell due to AstraZeneca's 8% drop after a failed clinical trial for a heart disease drug, impacting its market value by £20 billion. Meanwhile, Computacenter surged over 13% following a strong trading update, and US semiconductor stocks rallied on renewed AI demand. Investors are also watching upcoming US and UK earnings reports and geopolitical tensions affecting oil prices. The UK government pressures pension funds to invest more in domestic companies amid market shifts.
Kailera Therapeutics recently closed at $18.51, down 2.5% for the week and 28.8% since its April IPO. The clinical-stage company, with no product revenue, holds $1.17 billion in cash and has a runway into mid-2028. Its lead drug, ribupatide, is in gl...
AstraZeneca retained a 'buy' rating from Citi despite mixed updates on its drug pipeline. Positive Phase III trial results for Tagrisso plus Orpathys in lung cancer showed significant survival benefits, with Citi estimating $500 million in peak sales...
AstraZeneca announced positive late-stage trial results for a two-drug combination treating a resistant form of lung cancer. The combo pairs Tagrisso, an established lung cancer pill, with Orpathys, a newer drug targeting the MET protein that causes ...
